Observational studyPloS one2026
Endoscopic ultrasound-guided liver biopsy using a 22G fine-needle biopsy needle and slow pull technique: A tertiary center experience.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic ultrasound-guided fine needle biopsy of the liver (EUS-LB) has emerged as a safe technique to obtain liver tissue for diagnosis of diffuse parenchymal and focal liver diseases. This method is widely accepted as it can overcome numerous shortcomings of percutaneous and transjugular liver biopsy (LB), but the technique is not well studied yet. There is a paucity of literature demonstrating that EUS-LB provides an adequate tissue sample for histologic analysis. Data on the use of 22G fine-needle biopsy (FNB) needle for liver biopsy is scarce.
objectiveThe aim of this study was to review the experience of a large tertiary referral center with EUS-LB and to evaluate the efficacy and safety of the method using a 22G FNB needle and slow pull technique for diffuse parenchymal diseases and focal liver lesions.
methodsWe conducted a retrospective observational study over a three-year period and included all consecutive patients who underwent EUS-LB for diffuse parenchymal disease or focal liver lesions using a 22G Franseen-tip needle and slow pull technique.
resultsA total of 72 patients were included in the study, of which 32 were males and 40 were females. The median age was 56.9 years. Adequate biopsy rates, as assessed by pathologists, were achieved in all 72 patients. Malignant disease was found in 55 (76.4%) patients and benign disease in 17 (23.6%). No adverse events were observed during the first 48 hours or within a 30-day follow-up.
conclusionsOur study illustrates that EUS-guided liver biopsy using a 22G FNB needle provides an adequate specimen for histologic analysis, shorter postprocedural recovery time, and is a safe and effective alternative to conventional methods of liver biopsy. The use of real-time imaging guidance with Doppler also helps to reduce adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.